Vaccines,
Journal Year:
2024,
Volume and Issue:
12(12), P. 1422 - 1422
Published: Dec. 17, 2024
Background/Objectives:
The
ongoing
COVID-19
pandemic
has
underscored
the
need
for
alternative
prophylactic
measures,
particularly
populations
whom
vaccines
may
not
be
effective
or
accessible.
This
study
aims
to
evaluate
efficacy
of
intranasally
administered
IgY
antibodies
derived
from
hen
egg
yolks
as
a
protective
agent
against
SARS-CoV-2
infection
in
Syrian
golden
hamsters,
well-established
animal
model
COVID-19.
Methods:
Hens
were
immunized
with
spike
protein
generate
antibodies.
These
extracted
yolks,
purified,
and
their
neutralizing
activity
was
tested
vitro.
hamsters
then
treated
before
being
challenged
SARS-CoV-2.
Viral
loads
quantified
using
droplet
digital
PCR
(ddPCR),
lung
pathology
assessed
through
histopathological
analysis.
Results:
vitro
assays
showed
that
effectively
neutralized
In
vivo
hamster
model,
treatment
led
significant
reduction
viral
marked
decrease
consolidation
inflammation
compared
positive
control
group.
Histopathological
findings
further
supported
role
reducing
damage
caused
by
Conclusions:
results
demonstrate
exhibit
strong
antiviral
can
significantly
reduce
associated
hamsters.
suggest
could
viable
option
preventing
infection,
individuals
who
cannot
receive
respond
vaccines.
Further
studies
are
warranted
optimize
dosage
explore
long-term
Journal of Agricultural and Food Chemistry,
Journal Year:
2023,
Volume and Issue:
71(13), P. 5053 - 5061
Published: March 24, 2023
The
immunoglobulin
Y
(IgY)
derived
from
hyperimmune
egg
yolk
is
a
promising
passive
immune
agent
to
combat
microbial
infections
in
humans
and
livestock.
Numerous
studies
have
been
performed
develop
specific
IgY
for
pathogen
control,
but
with
limited
success.
To
date,
the
efficacy
of
commercial
products,
which
are
all
delivered
through
an
oral
route,
has
not
approved
or
endorsed
by
any
regulatory
authorities.
Several
challenging
issues
IgY-based
immunization,
were
fully
recognized
holistically
discussed
previous
publications,
impeded
development
effective
products
animals.
This
review
summarizes
major
challenges
this
technology,
including
vivo
stability,
purification,
heterologous
immunogenicity,
repertoire
diversity
IgY.
tackle
these
challenges,
potential
solutions,
such
as
encapsulation
technologies
stabilize
IgY,
discussed.
Exploration
technology
COVID-19
pandemic
also
updated
review.
Antibodies,
Journal Year:
2022,
Volume and Issue:
11(4), P. 62 - 62
Published: Sept. 29, 2022
Since
the
discovery
of
antibodies
by
Emil
Von
Behring
and
Shibasaburo
Kitasato
during
19th
century,
their
potential
for
use
as
biotechnological
reagents
has
been
exploited
in
different
fields,
such
basic
applied
research,
diagnosis,
treatment
multiple
diseases.
Antibodies
are
relatively
easy
to
obtain
from
any
species
with
an
adaptive
immune
system,
but
birds
animals
characterized
care
maintenance.
In
addition,
they
produce
can
be
purified
egg
yolk,
allowing
a
system
obtaining
them
without
performing
invasive
practices,
which
favors
three
"rs"
animal
experimentation,
i.e.,
replacing,
reducing,
refining.
this
work,
we
carry
out
brief
descriptive
review
most
outstanding
characteristics
so-called
"IgY
technology"
IgY
human
beings
animals.
Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: May 10, 2022
Within
the
framework
of
current
COVID-19
pandemic,
there
is
a
race
against
time
to
find
therapies
for
outbreak
be
controlled.
Since
vaccines
are
still
tedious
develop
and
partially
available
low-income
countries,
passive
immunity
based
on
egg-yolk
antibodies
(IgY)
presented
as
suitable
approach
preclude
potential
death
infected
patients,
its
high
specificity/avidity/production
yield,
cost-effective
manufacture,
ease
administration.
In
present
study,
IgY
recombinant
RBD
protein
SARS-CoV-2
were
produced
in
specific-pathogen-free
chickens
purified
from
eggs
using
biocompatible
method.
vitro
immunoreactivity
was
tested,
finding
recognition
neutralization
values.
Safety
also
demonstrated
prior
efficacy
evaluation,
which
body
weight,
kinematics,
histopathological
assessments
hamsters
challenged
with
performed,
showing
protective
effect
administering
intranasally
both
prophylactic
treatment
or
post-infection
treatment.
The
results
this
study
showed
that
delivered
has
aid
prevention
overcoming
infection,
should
very
useful
control
advance
pandemic
associated
mortality.
Research Square (Research Square),
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 19, 2025
Despite
the
overall
positive
outcomes
in
hospitalization
and
mortality
rates
from
COVID-19
vaccines,
infections
remained
prevalent
around
world
highlighting
need
for
alternative
control
strategies.
Passive
immunization
with
chicken
IgY
has
long
served
as
a
feasible
countermeasure,
which
gained
further
popularity
research
community
during
recent
pandemic.
Here
we
demonstrate
first
time
scalability
of
anti-COVID-19
production
effective
distribution
potential
use
large
populations.
Over
70,000
chickens
were
immunized
against
SARS-CoV-2
S1
antigen
to
produce
eggs
containing
anti-S1
IgY.
The
resulting
egg
yolk
powder
was
formulated
into
commercially
acceptable
tablets
human
consumption.
QC
stability
testing
showed
that
purified
maintained
activity
over
year.
batch
demonstrated
equal
immunoreactivity
virus
neutralization
all
leading
strains.
Our
results
feasibility
manufacturing
edible
tablets,
can
now
be
employed
block
viral
infectivity
transmission
major
strains
affordably
effectively
manner
both
developed
developing
countries.
Viruses,
Journal Year:
2022,
Volume and Issue:
14(5), P. 1060 - 1060
Published: May 16, 2022
Currently,
SARS-CoV-2
spike
receptor-binding-domain
(RBD)-based
vaccines
are
considered
one
of
the
most
effective
weapons
against
COVID-19.
During
first
step
assessing
vaccine
immunogenicity,
a
mouse
model
is
often
used.
In
this
paper,
we
tested
use
five
experimental
animals
(mice,
hamsters,
rabbits,
ferrets,
and
chickens)
for
RBD
immunogenicity
assessments.
The
humoral
immune
response
was
evaluated
by
ELISA
virus-neutralization
assays.
data
obtained
show
hamsters
to
be
least
suitable
candidates
testing
and,
hence,
protective
efficacy
RBD-based
vaccines.
